Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study led by Professor Jonathan Rees, NDORMS will look into the benefits of shoulder surgery following first time traumatic dislocation of the shoulder compared to non-operative treatments such as physiotherapy in preventing further problems.

Professor Rees says: "We are delighted to have won this commissioned award from the HTA and look forward to answering this important UK shoulder healthcare question. The results of this study will provide very useful evidence and information to doctors treating this condition and to patients suffering with it."

Traumatic anterior shoulder dislocations are the most common form of joint dislocations seen in hospital A+E departments however there is still debate on the best treatment to take after the first incident.

In this form of dislocation, the humeral head (top end of the arm bone at the shoulder) is forced out of the shoulder socket frontwards. This can happen after sport injuries or falls and is most common in younger patients. The injury is very painful and the shoulder often stays dislocated until it is reduced or put back in hospital.

In addition to causing a lot of pain, stress and disability, this type of injury often causes the joint to remain unstable and more dislocations can occur. Due to the risk of further dislocations, surgery has become more common as a treatment, but it is still not known which patients are best treated with physiotherapy and which patients are best treated first with surgery.

The UK TASH-D (Treatment of first-time traumatic Anterior SHoulder Dislocation) team will be using information that is already available within the NHS on young patients aged 16-35 years who suffer with traumatic shoulder dislocations to determine whether shoulder surgery is better than non-operative treatments.

The study will also identify risk factors for re-dislocation such as occupation or sport that may influence the type of treatment.

UK TASH-D is funded by the NIHR Health Technology Assessment programme, with HTA Project Reference 14/160/01.

UK_TASH-D

Similar stories

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?

Professor Michael Dustin elected to the National Academy of Sciences

Awards Kennedy Main

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.